Tag: rights

ATLANTA, July 22, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) complied with federal securities laws. On July 22, 2025, Replimune announced it received a Complete Response Letter (“CRL”) from the FDA regarding the Biologics License Application (“BLA”) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. In the CRL, the FDA indicated “that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.” Following this news, the price of the Company’s stock dropped. 

8.3

DUBLIN, Ireland, July 22, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fusion Fuel Green PLC (NASDAQ: HTOO) (“Fusion Fuel” or the “Company”), a provider of integrated energy solutions, today announced that Bright Hydrogen Solutions Ltd (“BrightHy Solutions”), a Fusion Fuel subsidiary and provider of hydrogen solutions, executed a non-binding Term Sheet (the “Term Sheet”) outlining the terms of a strategic partnership focused on investments in hydrogen projects and infrastructure with an integrated green energy technologies provider (the “Partner”). As contemplated by the Term Sheet, subject to execution of one or more binding agreements, the Partner would commit up to €30 million in capital over four years to be invested in certain hydrogen projects. These investments are expected to be channeled through special purpose vehicles held by a newly created investment entity to be majority-owned by the Partner.

FORM 8.5 (EPT/RI)

MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated otherwise.